215 related articles for article (PubMed ID: 27770190)
1. A FAS-ligand variant associated with autoimmune lymphoproliferative syndrome in cats.
Aberdein D; Munday JS; Gandolfi B; Dittmer KE; Malik R; Garrick DJ; Lyons LA;
Mamm Genome; 2017 Feb; 28(1-2):47-55. PubMed ID: 27770190
[TBL] [Abstract][Full Text] [Related]
2. Frequency of a FAS ligand gene variant associated with inherited feline autoimmune lymphoproliferative syndrome in British shorthair cats in New Zealand.
Aberdein D; Munday JS; Dittmer KE; Heathcott RW; Lyons LA
N Z Vet J; 2017 Nov; 65(6):327-331. PubMed ID: 28814155
[TBL] [Abstract][Full Text] [Related]
3. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.
Nabhani S; Ginzel S; Miskin H; Revel-Vilk S; Harlev D; Fleckenstein B; Hönscheid A; Oommen PT; Kuhlen M; Thiele R; Laws HJ; Borkhardt A; Stepensky P; Fischer U
Haematologica; 2015 Sep; 100(9):1189-98. PubMed ID: 26113417
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation.
Magerus-Chatinet A; Stolzenberg MC; Lanzarotti N; Neven B; Daussy C; Picard C; Neveux N; Desai M; Rao M; Ghosh K; Madkaikar M; Fischer A; Rieux-Laucat F
J Allergy Clin Immunol; 2013 Feb; 131(2):486-90. PubMed ID: 22857792
[TBL] [Abstract][Full Text] [Related]
5. FAS-mediated apoptosis impairment in patients with ALPS/ALPS-like phenotype carrying variants on CASP10 gene.
Miano M; Cappelli E; Pezzulla A; Venè R; Grossi A; Terranova P; Palmisani E; Maggiore R; Guardo D; Lanza T; Calvillo M; Micalizzi C; Pierri F; Vernarecci C; Beccaria A; Corsolini F; Lanciotti M; Russo G; Ceccherini I; Dufour C; Fioredda F
Br J Haematol; 2019 Nov; 187(4):502-508. PubMed ID: 31309545
[TBL] [Abstract][Full Text] [Related]
6. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.
Rieux-Laucat F; Magérus-Chatinet A; Neven B
J Clin Immunol; 2018 Jul; 38(5):558-568. PubMed ID: 29911256
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance.
Hsu AP; Dowdell KC; Davis J; Niemela JE; Anderson SM; Shaw PA; Rao VK; Puck JM
Genet Med; 2012 Jan; 14(1):81-9. PubMed ID: 22237435
[TBL] [Abstract][Full Text] [Related]
8. Rare splicing defects of FAS underly severe recessive autoimmune lymphoproliferative syndrome.
Agrebi N; Ben-Mustapha I; Matoussi N; Dhouib N; Ben-Ali M; Mekki N; Ben-Ahmed M; Larguèche B; Ben Becher S; Béjaoui M; Barbouche MR
Clin Immunol; 2017 Oct; 183():17-23. PubMed ID: 28668589
[TBL] [Abstract][Full Text] [Related]
9. Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations.
Maccari ME; Schneider P; Smulski CR; Meinhardt A; Pinto F; Gonzalez-Granado LI; Schuetz C; Sica MP; Gross M; Fuchs I; Kury P; Heeg M; Vocat T; Willen L; Thomas C; Hühn R; Magerus A; Lorenz M; Schwarz K; Rieux-Laucat F; Ehl S; Rensing-Ehl A
J Allergy Clin Immunol; 2023 May; 151(5):1391-1401.e7. PubMed ID: 36621650
[TBL] [Abstract][Full Text] [Related]
10. A Novel and Likely Inherited Lymphoproliferative Disease in British Shorthair Kittens.
Aberdein D; Munday JS; Fairley RA; Vernau W; Thompson KG
Vet Pathol; 2015 Nov; 52(6):1176-82. PubMed ID: 26041772
[TBL] [Abstract][Full Text] [Related]
11. Next Generation Sequencing for Detecting Somatic
López-Nevado M; Docampo-Cordeiro J; Ramos JT; Rodríguez-Pena R; Gil-López C; Sánchez-Ramón S; Gil-Herrera J; Díaz-Madroñero MJ; Delgado-Martín MA; Morales-Pérez P; Paz-Artal E; Magerus A; Rieux-Laucat F; Allende LM
Front Immunol; 2021; 12():656356. PubMed ID: 33995372
[TBL] [Abstract][Full Text] [Related]
12. Study of the potential role of CASPASE-10 mutations in the development of autoimmune lymphoproliferative syndrome.
Consonni F; Moreno S; Vinuales Colell B; Stolzenberg MC; Fernandes A; Parisot M; Masson C; Neveux N; Rosain J; Bamberger S; Vigue MG; Malphettes M; Quartier P; Picard C; Rieux-Laucat F; Magerus A
Cell Death Dis; 2024 May; 15(5):315. PubMed ID: 38704374
[TBL] [Abstract][Full Text] [Related]
13. FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome.
Kuehn HS; Caminha I; Niemela JE; Rao VK; Davis J; Fleisher TA; Oliveira JB
J Immunol; 2011 May; 186(10):6035-43. PubMed ID: 21490157
[TBL] [Abstract][Full Text] [Related]
14. Novel insights into FAS defects underlying autoimmune lymphoproliferative syndrome revealed by studies in consanguineous patients.
Ben-Mustapha I; Agrebi N; Barbouche MR
J Leukoc Biol; 2018 Mar; 103(3):501-508. PubMed ID: 29345341
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of miR-146a/FAS and miR-21/FASLG axes in autoimmune lymphoproliferative syndrome due to FAS mutation (ALPS-FAS).
Marega LF; Teocchi MA; Dos Santos Vilela MM
Clin Exp Immunol; 2016 Aug; 185(2):148-53. PubMed ID: 27060458
[TBL] [Abstract][Full Text] [Related]
16. Disturbed B-lymphocyte selection in autoimmune lymphoproliferative syndrome.
Janda A; Schwarz K; van der Burg M; Vach W; Ijspeert H; Lorenz MR; Elgizouli M; Pieper K; Fisch P; Hagel J; Lorenzetti R; Seidl M; Roesler J; Hauck F; Traggiai E; Speckmann C; Rensing-Ehl A; Ehl S; Eibel H; Rizzi M
Blood; 2016 May; 127(18):2193-202. PubMed ID: 26907631
[TBL] [Abstract][Full Text] [Related]
17. Somatic loss of heterozygosity, but not haploinsufficiency alone, leads to full-blown autoimmune lymphoproliferative syndrome in 1 of 12 family members with FAS start codon mutation.
Hauck F; Magerus-Chatinet A; Vicca S; Rensing-Ehl A; Roesen-Wolff A; Roesler J; Rieux-Laucat F
Clin Immunol; 2013 Apr; 147(1):61-68. PubMed ID: 23524443
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation.
Martínez-Feito A; Melero J; Mora-Díaz S; Rodríguez-Vigil C; Elduayen R; González-Granado LI; Pérez-Méndez D; Sánchez-Zapardiel E; Ruiz-García R; Menchén M; Díaz-Madroñero J; Paz-Artal E; Del Orbe-Barreto R; Riñón M; Allende LM
Immunobiology; 2016 Jan; 221(1):40-7. PubMed ID: 26323380
[TBL] [Abstract][Full Text] [Related]
19. STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds.
Nabhani S; Schipp C; Miskin H; Levin C; Postovsky S; Dujovny T; Koren A; Harlev D; Bis AM; Auer F; Keller B; Warnatz K; Gombert M; Ginzel S; Borkhardt A; Stepensky P; Fischer U
Clin Immunol; 2017 Aug; 181():32-42. PubMed ID: 28579554
[TBL] [Abstract][Full Text] [Related]
20. A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome.
Nabhani S; Hönscheid A; Oommen PT; Fleckenstein B; Schaper J; Kuhlen M; Laws HJ; Borkhardt A; Fischer U
Clin Immunol; 2014 Dec; 155(2):231-7. PubMed ID: 25451160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
